(Q53394448)

English

Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12627987

Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12627987

peginterferon alfa-2a

1 reference

based on heuristic

inferred from title

2

object named as

Stefan Zeuzem

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

Dennis A Revicki

10

object named as

Dennis A Revicki

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12627987

author name string

Jens Rasenack

1

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12627987

S Victor Feinman

3

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12627987

E Jenny Heathcote

4

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12627987

Michael Manns

5

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12627987

Eric M Yoshida

6

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12627987

Mark G Swain

7

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12627987

Edward Gane

8

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12627987

Moises Diago

9

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12627987

Amy Lin

11

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12627987

Neil Wintfeld

12

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12627987

Jesse Green

13

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12627987

publication date

1 January 2003

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12627987

PharmacoEconomics

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12627987

21

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12627987

5

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12627987

341-349

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12627987

Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Musculoskeletal pain and fatigue are associated with chronic hepatitis C: a report of 239 hepatology clinic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural history of HCV infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Side effects of alpha interferon in chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy of hepatitis C: interferon alfa-n1 trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00019053-200321050-00005

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12627987

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/12627987

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53394448&oldid=2212104640"